Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU

What Was Tested

The paper reports a study of Goserelin, published as a phase 2 clinical trial.

Who Took Part

According to the abstract, 24 patients were involved.

PubMed indexes the participants as adults, middle-aged adults, older adults and people over 80, both men and women.

Patients with histologically confirmed unresectable or recurrent/metastatic salivary gland carcinoma with AR expression were included.

The primary endpoint was the overall response rate (ORR) according to RECIST v1.1 by an independent central radiology review in the first 24 response-evaluable (RE) patients who had been observed at least 24 weeks from study initiation (primary RE patients).

How the Study Was Run

In design terms this was an open-label and multicenter study.

Being open-label, the Goserelin study did not mask who received what.

Running at several centres spread the Goserelin study over different clinics and patient groups.

This trial was an open-label, single-arm, multicenter phase II study.

What Was Measured

PubMed files the paper under topics including Salivary Gland Neoplasms, Receptors, Androgen, Thiohydantoins, Goserelin, Antineoplastic Combined Chemotherapy Protocols and Neoplasm Recurrence, Local.

What This Means in Plain Language

The paper is an open-label and multicenter study of Goserelin in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Clinical cancer research : an official journal of the American Association for Cancer Research), a journal based in United States.

More context: the Goserelin compound page, all human trials.